Specialty and generic drugmaker Actavis plc reported another monster quarter last week. Here are five things management wants investors to know going forward.
Valeant Pharmaceuticals' takeover bid for Allergan has turned hostile in more ways than one.
Biotech can be a tough sector for many investors. Here, our analysts share their three favorite picks as we go into November.
Aegerion Pharmaceuticals is October's worst biotech stock after reporting weaker-than-expected third-quarter results. Find out whether this dip is a buying opportunity or a warning sign of more weakness to come.
Alnylam's third-quarter earnings call was all about the pipeline data.
Actavis posted third-quarter earnings this morning. Here's what you need to know.
Following another strong quarterly earnings report, here are five things Celgene's management team would like investors to know.
NPS Pharmaceuticals, ANI Pharmaceuticals, and Insys Therapeutics are expected to see their earnings jump in the coming year.
Revlimid might be the flagship, but growth will come from the newer drugs.
AbbVie's board recommends that the company not purchase Shire.